Effect of oral diclofenac intake on faecal calprotectin

References

• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys. Gut 2006;55:436–1.
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.
   PubMedGoogle Scholar
• Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000;47:506–13.
   PubMed Web of Science ®Google Scholar
• von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007;102:803–13.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Bjarnason I. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc) 2001;37:85–96.
   PubMed Web of Science ®Google Scholar
• Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017–20.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Gastrointestinal damage from nonsteroidal anti-inflammatory drugs. Toxicol Pathol 1988;16:251–9.
   PubMed Web of Science ®Google Scholar
• Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996;6:489–504.
   PubMedGoogle Scholar
• Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362–6.
   PubMed Web of Science ®Google Scholar
• Meling TR, Aabakken L, Røseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996;31:339–44.
   PubMed Web of Science ®Google Scholar
• Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172–8.
   PubMed Web of Science ®Google Scholar
• Thornjóðleifsson B, Theodórs A, Bjarnason I. The effect of diclofenac on the small intestine studied by wireless endoscopy. Laeknabladid 2004;90:689–93.
   PubMedGoogle Scholar
• Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Aisenberg J, Bhadra P, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther 2007;25:1211–22.
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, McAlindon M, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008;6:536–44.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:196–202.
   PubMed Web of Science ®Google Scholar
• Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006;101:701–10.
   PubMed Web of Science ®Google Scholar
• Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314–22.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133–41.
   PubMed Web of Science ®Google Scholar
• Kuramoto T, Umegaki E, Nouda S, Narabayashi K, Kojima Y, Yoda Y, et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol 2013;13:85.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol 2003;15:573–4; author reply 574.
   PubMed Web of Science ®Google Scholar
• Husebye E, Tøn H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683–7.
   PubMed Web of Science ®Google Scholar
• Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis 2010;16:1091–2.
   PubMed Web of Science ®Google Scholar
• Naismith GD, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, et al. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn’s disease. Aliment Pharmacol Ther 2013;37:613–21.
   PubMed Web of Science ®Google Scholar
• Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:xv–xix.
   PubMed Web of Science ®Google Scholar
• Mahjoub FE, Zahedi N, Ashjai B, Ashtiani MT, Farahmand F, Monajemzadeh M, et al. Role of fecal calprotectin in differentiating between Hirschsprung’s disease and functional constipation. Korean J Gastroenterol 2013;62:288–91.
   PubMedGoogle Scholar